Imiquimod is Used for treating skin conditions caused by certain types of viruses. It was first introduced by Bausch Health Us Llc in its drug Aldara on Feb 27, 1997. Another drug containing Imiquimod is Zyclara. 9 different companies have introduced drugs containing Imiquimod.

Imiquimod Patents

Given below is the list of patents protecting Imiquimod, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Aldara	US7696159	Treatment for basal cell carcinoma	Apr 01, 2024 (Expired)	Bausch
Aldara	US7696159 (Pediatric)	Treatment for basal cell carcinoma	Oct 01, 2024	Bausch
Zyclara	US10238644	2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec 11, 2029	Bausch
Zyclara	US10238645	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Aug 18, 2029	Bausch
Zyclara	US10918635	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Apr 30, 2030	Bausch
Zyclara	US11202752	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	Apr 30, 2030	Bausch
Zyclara	US11318130	2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec 11, 2029	Bausch
Zyclara	US11850245	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Apr 30, 2030	Bausch
Zyclara	US8222270	2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod	Dec 11, 2029	Bausch
Zyclara	US8236816	2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod	Dec 11, 2029	Bausch
Zyclara	US8299109	Method of treating actinic keratosis with 3.75% imiquimod cream	Dec 11, 2029	Bausch
Zyclara	US8598196	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	Aug 18, 2029	Bausch

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Imiquimod's patents.

Latest Legal Activities on Imiquimod's Patents

Given below is the list recent legal activities going on the following patents of Imiquimod.

Event	Date	Patent/Publication
Today's Critical Events
Payment of Maintenance Fee, 12th Year, Large Entity	20 Mar, 2024	US8299109(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	23 Jan, 2024	US8236816(Litigated)
Patent Issue Date Used in PTA Calculation	26 Dec, 2023	US11850245
Recordation of Patent Grant Mailed	26 Dec, 2023	US11850245
Mail Patent eGrant Notification	26 Dec, 2023	US11850245
Email Notification	26 Dec, 2023	US11850245
Recordation of Patent eGrant	26 Dec, 2023	US11850245
Patent eGrant Notification	26 Dec, 2023	US11850245
Payment of Maintenance Fee, 12th Year, Large Entity	19 Dec, 2023	US8222270
Email Notification	07 Dec, 2023	US11850245

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳